This site is intended for healthcare professionals

CTI BioPharma announces FDA acceptance of NDA granted with priority review of pacritinib for treatment of patients with myelofibrosis.

Read time: 1 mins
Last updated:2nd Jun 2021
Published:2nd Jun 2021
CTI BioPharma Corp. announced that the FDA has accepted its New Drug Application (NDA) for pacritinib as a treatment for myelofibrosis patients with severe thrombocytopenia (platelet counts less than 50 x 109/L), with the NDA being granted Priority Review.
Condition: Myelofibrosis
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest